The evolution of CLL treatment

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer, effective in some

US breast cancer cases expected to increase by as much as 50 percent by 2030

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication

Pembrolizumab promising for lung cancer, clinical outcomes correlate with biomarker

Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial

How to decide the treatment of CLL in 2015

ecancermedicalscience editor's choice for March 2015

Expert insight: Radiation oncology with the Scientific Director of the IEO

BRAF 'behind the scenes' in melanoma: A scientific story of discovery

Connecting science, practice and patient outcomes: Use of BRAF inhibitors for treating metastatic melanoma in clinical practice